Xeris Biopharma (XERS) COO gets 168,463 RSUs and 225,225 options

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. executive equity activity: President and Chief Operating Officer Kevin McCulloch reported new stock-based compensation and related tax share withholdings. On January 30, 2026, he received 168,463 shares of common stock through a restricted stock unit grant that vests in three equal annual installments, subject to continued employment.

On the same date, he was granted 225,225 stock options with a $7.36 exercise price, also vesting in three equal annual installments, subject to continued service. On January 31, 2026, the company withheld 68,454, 30,289, and 27,319 shares at $7.36 per share to cover income tax obligations on vested restricted stock units. After these transactions, he directly owned 1,727,827 common shares.

The filing also notes 25,000 shares held indirectly by his spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider McCulloch Kevin

Role See Remarks

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	68,454	$7.36	$504K
Tax Withholding	Common Stock	30,289	$7.36	$223K
Tax Withholding	Common Stock	27,319	$7.36	$201K
Grant/Award	Stock Option (Right to Buy)	225,225	$0.00	--
Grant/Award	Common Stock	168,463	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,785,435 shares (Direct); Stock Option (Right to Buy) — 225,225 shares (Direct); Common Stock — 25,000 shares (Indirect, By Spouse)

Footnotes (1)

1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		168,463(1)	A	$0	1,853,889	D
Common Stock	01/31/2026		F		68,454(2)	D	$7.36	1,785,435	D
Common Stock	01/31/2026		F		30,289(2)	D	$7.36	1,755,146	D
Common Stock	01/31/2026		F		27,319(2)	D	$7.36	1,727,827	D
Common Stock								25,000(3)	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.36	01/30/2026		A		225,225		(4)	01/30/2036	Common Stock	225,225	$0	225,225	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.

2. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.

3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

4. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Xeris Biopharma (XERS) report for Kevin McCulloch?

Kevin McCulloch reported new equity awards and tax-related share withholdings. He received restricted stock units and stock options, while the company withheld shares to cover income taxes on vested awards, and he reported updated direct and indirect share holdings.

How many Xeris Biopharma (XERS) shares did Kevin McCulloch acquire through restricted stock units?

He acquired 168,463 Xeris Biopharma common shares via a restricted stock unit grant. Each unit converts into one share, and the award vests in three equal annual installments, contingent on continued employment through each vesting date under the company’s 2018 plan.

What stock options did Kevin McCulloch receive from Xeris Biopharma (XERS)?

He received 225,225 stock options with a $7.36 exercise price. These options were granted under Xeris Biopharma’s 2018 Stock Option and Incentive Plan and are scheduled to vest in equal annual installments over three years, subject to continued service.

Why were Xeris Biopharma (XERS) shares withheld from Kevin McCulloch on January 31, 2026?

Shares were withheld to satisfy income tax and withholding obligations on vested restricted stock units as of January 31, 2026. The company withheld blocks of 68,454, 30,289, and 27,319 shares at $7.36 per share in connection with the net settlement.

How many Xeris Biopharma (XERS) shares does Kevin McCulloch own after these transactions?

Following the reported transactions, he directly owned 1,727,827 Xeris Biopharma common shares. The filing also lists 25,000 additional shares held indirectly by his spouse, with beneficial ownership disclaimed except to the extent of his pecuniary interest.

How are Kevin McCulloch’s spouse-held Xeris Biopharma (XERS) shares treated in the Form 4?

The Form 4 reports 25,000 Xeris Biopharma shares held indirectly by his spouse. McCulloch disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, clarifying that their inclusion does not imply full beneficial ownership under Section 16.